The burden of disease of retinal vein occlusion: Review of the literature

Eye

Volumn 25, Issue 8, 2011, Pages 981-988

  Laouri, M ^a   Chen, E ^a   Looman, M ^a   Gallagher, M ^b  

^a Quorum Consulting   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

burden; cost; epidemiology; retinal vein occlusion

Indexed keywords

DEXAMETHASONE; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

BRANCH RETINAL VEIN OCCLUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL RETINA VEIN OCCLUSION; COST OF ILLNESS; DECISION MAKING; DEGENERATION; DISEASE COURSE; EYE DISEASE; HEALTH CARE COST; HUMAN; INCIDENCE; LASER COAGULATION; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; RACE DIFFERENCE; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; VISUAL ACUITY;

EID: 80051776549     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.92     Document Type: Review

References (39)

1. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117(6): 1094-1101
2. The Royal College of Ophthalmologists. Interim guidelines for management of retinal vein occlusion. 2009. Available at: http://www.rcophth.ac.uk. Accessed June 2010.
3. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117(6): 1113-1123
4. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117(2): 313-319
5. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114(10): 1243-1247 (Pubitemid 26338856)
6. Liu W, Xu L, Jonas JB. Vein occlusion in Chinese subjects. Ophthalmology 2007; 114(9): 1795-1796 (Pubitemid 47332672)
7. Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci 2010; 51(6): 3205-3209.
8. Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM et al. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol 2008; 92(10): 1316-1319
9. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-141
10. Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008; 49(10): 4297-4302
11. Wong TY, Larsen EK, Klein R, Mitchell P, Couper DJ, Klein BE et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005; 112(4): 540-547 (Pubitemid 41108850)
12. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006; 124(5): 726-732
13. Arakawa S, Yasuda M, Kiyohara Y, Hata Y, Ishibashi T. Nine-year incidence and risk factors for retinal vein occlusion in a general Japanese population: the Hisayama Study. Invest Ophthalmol Vis Sci 2009; 50, E-abstract 3727
14. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126(4): 513-518 (Pubitemid 351549845)
15. Ho JD, Tsai CY, Liou SW, Tsai RJ, Lin HC. Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan. Am J Ophthalmol 2008; 145(4): 722-728
16. Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Visionrelated quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003; 121(9): 1297-1302 (Pubitemid 37128408)
17. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol 2010; 94(3): 319-323
18. Chang MA, Fine HF, Bass E, Bressler SB, Schachat AP, Solomon SD et al. Patients preferences in choosing therapy for retinal vein occlusions. Retina 2007; 27(6): 789-797 (Pubitemid 47051777)
19. Rentz AM, Kowalski J, Revicki D, Loewenstein A, Blumenkranz MS, Yoon Y et al. Normative comparison of generic- and vision-targeted health-related quality of life (HRQL) outcomes in patients with vision loss due to macular edema following retinal vein occlusion. Invest Ophthalmol Vis Sci 2010; 51, E-abstract 4728
20. Varma R, Bressler NM, Suner IJ, Lee P, Dolan CM, Ward J et al. Ranibizumab improves patient-reported near and distance vision activities in patients with macular edema following retinal vein occlusion. Invest Ophthalmol Vis Sci 2010; 51, E-abstract 5212
21. Hornberger JC, Shewade A, Doberne JW, Kowalski J, Nguyen H. A systematic literature review of utilities associated with visual acuity in retinal diseases. Invest Ophthalmol Vis Sci 2008; 49, E-abstract 4478
22. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131(1): 61-77 (Pubitemid 32037010)
23. Martin SC, Butcher A, Martin N, Farmer J, Dobson PM, Bartlett WA et al. Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol 2002; 86(7): 774-776 (Pubitemid 34713165)
24. Doubal FN, Hokke PE, Wardlaw JM. Retinal microvascular abnormalities and stroke: a systematic review. J Neurol Neurosurg Psychiatry 2009; 80(2): 158-165
25. Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol 2009; 147(2): 283-290
26. Hu CC, Ho JD, Lin HC. Retinal vein occlusion and the risk of acute myocardial infarction (correction of infraction): a 3-year follow-up study. Br J Ophthalmol 2009; 93(6): 717-720
27. National Health Service. 2010 Annual Evidence Update on Retinal Vein Occlusion: cardiovascular morbidity and mortality associated with retinal vein occlusion. Available at http://www.library.nhs.uk/eyes. Accessed June 2010
28. Mansour AM, Walsh JB, Henkind P. Mortality and morbidity in patients with central retinal vein occlusion. Ophthalmologica 1992; 204(4): 199-203
29. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BE et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114(3): 520-524 (Pubitemid 46282956)
30. Tsaloumas MD, Kirwan J, Vinall H, OLeary MB, Prior P, Kritzinger EE et al. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye (Lond) 2000; 14(Part 6): 821-827 (Pubitemid 32007785)
31. Christoffersen N, Gade E, Knudsen L, Juel K, Larsen M. Mortality in patients with branch retinal vein occlusion. Ophthalmology 2007; 114(6): 1186-1189 (Pubitemid 46829384)
32. Haller JA, Bandello F, Belfort Jr. R, Blumenkranz MS, Gillies M, Heier J et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134.e3-1146.e3
33. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 2010; 117(6): 1124.e1-1133.e1
34. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema Following branch retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 2010; 117(6): 1102.e1-1112.e1
35. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127(9): 1101-1114
36. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127(9): 1115-1128
37. The Royal College of Ophthalmologists. Interim guidelines for management of retinal vein occlusion. 2010. Available at: http://www.rcophth.ac.uk. Accessed March 2011.
38. Fekrat S, Shea AM, Hammill BG, Nguyen H, Kowalski JW, Schulman KA et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin 2010; 26(1): 223-230
39. Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiol 2002; 9(1): 1-10 (Pubitemid 34098649)